She doesn't own this sector because of concerns (peak auto, tariffs, GM closings). But if she were to buy this sector, this would be her choice, because they have a global presence, especially Europe where they can improve their margins.

Transitioning from hardware to software and seeing some growth. The valuation is attractive, but other names in this tech space are better.

A defensive play. They're well-positioned in western Canada even with the low oil prices; they're still drilling there. They operates pipelines, processing plants, midstream operations. This year, they enjoyed strong cash flow growth and they believe they can continue to grow that by 10% annually over the next few years, and grow their dividend by 10%. Strong balance sheet with a 53% payout ratio. (Analysts’ price target is $54.11)

She bought it during the October pullback. Their cloud service is second only behind Amazon. They've transitioned their Office products to become a recurring revenue stream. Definite growth will continue. Strong balance sheet with $7 net cash/share. They can fund their growth without taking on debt. (Analysts’ price target is $125.63)

A pure water player--transpor and treat water, a scare commodity. It's pulled back to a good entry point now. Good growth in the U.S. where they refurbish their water infrastructure Emerging markets are 20% of their revenues where they are still building their infrastructure, so that's another plus. (Analysts’ price target is $78.47)

He got into DOL a little late, then lost money right before the summer short report. He sold. DOL has been increasing prices very slowly, but so has Walmart. Bay St. is still positive on DOL. Wait until tax-loss selling is over and see what happens. DOL still has room to grow in Canada. He isn't worried about Dollar Tree being a competitor in Canada.

2019 outlook? The US healthcare sector has been very defensive in this market; they're not as off other sectors. The sector went sideways during the 2016 US election campaign. PFE has announced the price of 40-50 of their drugs will be raised. Plenty of runway in this company. But in 2019, if there's a market recovery, money will flow out of healthcare and back into tech. But you're good to own this.